U.S. Drug Patent 9,567,582: Claim Scope, RNAi Coverage, Patent Landscape and Generic Risk

U.S. Patent No. 9,567,582 protects broad classes of synthetic or non-enzymatically processed double-stranded RNA molecules used for target-specific RNA interference. The core limitations are a 19-52 nucleotide strand or double-stranded region, at least one 3′ overhang, and RNAi activity. Dependent claims add 1-5 nucleotide overhangs, 2′-modified sugars, phosphorothioate backbones, modified nucleobases, therapeutic and diagnostic compositions, and activity against mammalian, human, plant, viral, tumor-associated, autoimmune, and pathogen-associated RNA targets.

The patent is platform-oriented. It does not identify a particular drug sequence, disease, delivery system, conjugate, or formulation. Its commercial relevance therefore depends on whether a marketed or development-stage siRNA product practices the structural limitations and whether the patent remains enforceable against the relevant product.

What does U.S. Patent 9,567,582 protect?

The independent claims create three principal protection categories:

Claim group	Independent claim	Principal subject matter
Structural dsRNA	1	Double-stranded RNA with 19-52 nucleotide strands, a 3′ overhang, non-enzymatic processing, and target-specific RNAi
Structural dsRNA with defined duplex	31	19-52 base-pair double-stranded region, 3′ overhang, non-enzymatic processing, and RNAi activity
Synthetic modified dsRNA	54	Synthetic dsRNA with 19-52 nucleotide strands, 3′ overhang, at least one nucleotide analogue, and RNAi activity

Claims 1 and 31 are the broadest practical entry points. Claim 54 is narrower because it requires both synthetic production and at least one nucleotide analogue.

The claims are composition claims. They do not require a particular method of administration, target gene, disease, delivery vehicle, dose, or patient population in the independent claims.

What are the key limitations of claim 1?

Claim 1 requires all of the following:

An isolated double-stranded RNA molecule.
A sense strand and an antisense strand.
Each strand containing 19-52 nucleotides.
At least one 3′ overhang.
Non-enzymatic processing.
Capability for target-specific RNA interference.

A product must satisfy every limitation of the claim, either literally or potentially under the doctrine of equivalents, for direct infringement to arise. The claim does not require the sense strand to be identical to a target mRNA or the antisense strand to be fully complementary. Those features appear in dependent claims 24 and 25.

The phrase "capable of target-specific RNA interference" is functional. It focuses on the molecule's demonstrated or inherent activity rather than merely its sequence architecture. A nonfunctional duplex would face a substantial written-description, enablement, or infringement issue if the accused product cannot perform the claimed RNAi function.

How broad is the 19-52 nucleotide limitation?

The numerical range is broad compared with conventional 21-23 nucleotide siRNAs. It covers:

19-23 nucleotide duplexes commonly associated with canonical siRNA designs;
longer duplex strands extending through 24-52 nucleotides;
asymmetric strand lengths within the claimed range;
duplexes with one or more 3′ overhangs;
sequences directed to human, animal, plant, viral, tumor-associated, autoimmune, and pathogen-associated genes.

Claims 22 and 23 separately recite 19-25 nucleotide sense and antisense strands. These claims narrow the broader 19-52 nucleotide range and may be more relevant to conventional therapeutic siRNAs.

Claim 31 shifts the measurement from individual strand length to a double-stranded region of 19-52 base pairs. That language may reach molecules whose total strand lengths differ because of overhangs or other terminal structures.

What overhang structures are protected?

The patent claims several overhang configurations.

Claim	Overhang limitation
1	At least one 3′ overhang
2	1-5 nucleotides
4	1-3 nucleotides
14	Single 3′ overhang
15	Two nucleotides
29	Overhang in antisense strand
30	Overhang in sense strand
37	Single 3′ overhang
38	1-5 nucleotides
39	1-3 nucleotides
40	Two nucleotides
60	1-5 nucleotides

The two-nucleotide 3′ overhang is particularly important because it is a common structural characteristic of conventional siRNA molecules. A duplex with a two-nucleotide overhang may fall within claims 15 and 40 if the remaining limitations are met.

Claim 20 separately recites a blunt 3′ end. That claim creates a potential internal tension with the requirement in claim 1 for at least one 3′ overhang. The scope of claim 20 depends on how the patent distinguishes a blunt terminus from another 3′ overhang elsewhere in the molecule and on the construction of "at least one 3′ overhang."

What chemical modifications are covered?

Claims 6-9, 26-28, and 32-35 cover modified nucleotide chemistry. The principal categories are:

Modification	Claims	Commercial relevance
Sugar-modified ribonucleotide	7, 8, 33, 34	2′-O-methyl, 2′-fluoro, 2′-amino and related substitutions
Backbone-modified ribonucleotide	7, 9, 33, 35	Phosphorothioate and related backbone modifications
Nucleotide lacking 2′-hydroxyl	26	Broad functional category covering certain deoxy or modified sugars
Modified or non-naturally occurring nucleobase	52, 53	Base substitutions intended to alter stability, immunogenicity, or pairing
Terminal modification	18, 27, 28	Modification at the 5′ end, 3′ end, overhang, or sense-strand 3′ end
Stabilized overhang	5	Protection against degradation

The 2′-OH replacement language in claims 8 and 34 is structurally broad. It includes hydrogen, alkoxy, alkyl, halo, thiol, amino, substituted amino, and cyano substituents within the stated carbon limitations.

For modern siRNA products, the most important question is whether the accused molecule contains a claimed analogue at a claimed location. A product with 2′-O-methyl or 2′-fluoro modifications may implicate the modification claims, but the entire independent-claim architecture still must be satisfied.

Does the patent cover chemically synthesized siRNA?

Yes. Claims 54-62 specifically cover synthetic RNA molecules containing at least one nucleotide analogue.

Claim 54 requires:

an isolated dsRNA molecule;
19-52 nucleotide strands;
at least one 3′ overhang;
synthetic status;
at least one nucleotide analogue; and
target-specific RNAi capability.

Claims 55 and 56 narrow the manufacturing route by requiring chemical synthesis or excluding enzymatic transcription. These claims are directed to product characteristics and manufacturing provenance. They could be relevant to chemically manufactured active pharmaceutical ingredients, although proving the synthesis route may require discovery into manufacturing records.

Claim 63 and claim 64 address molecules enzymatically processed after administration. Those claims potentially reach products that are chemically prepared but undergo enzymatic processing in vivo.

What therapeutic and diagnostic uses are protected?

Claim 10 covers a pharmaceutical composition containing a claimed dsRNA and a pharmaceutical carrier. Claims 11 and 12 divide the composition into diagnostic and therapeutic applications.

Claims 44-51 and 45-53 extend the claimed RNA molecules to particular biological targets:

mammalian RNA;
human RNA;
plant RNA;
pathogen-associated genes;
viral genes;
tumor-associated genes; and
autoimmune disease-associated genes.

These claims are not disease-specific composition claims. They are RNAi product claims defined partly by the type of target RNA affected. A product directed to a human viral gene or tumor-associated gene could fall within the relevant dependent claims if the structural limitations are also satisfied.

The claims do not specifically cover delivery technologies such as lipid nanoparticles, GalNAc conjugates, antibodies, polymers, viral vectors, or cationic lipids. A delivery system may be protected by separate formulation, conjugate, particle, or method-of-use patents.

How does this patent compare with product-specific siRNA patents?

U.S. Patent 9,567,582 is best characterized as a foundational platform patent rather than a product patent.

Patent category	Typical claim focus	Relationship to U.S. 9,567,582
Platform siRNA patent	Duplex structure, overhang, chemical synthesis, RNAi activity	Potentially overlapping
Sequence patent	Specific guide and passenger sequences	Usually cumulative
Chemical-modification patent	Defined pattern of 2′-substitutions or terminal modifications	Potentially cumulative
Conjugate patent	Ligand-siRNA linkage, such as GalNAc	Usually separate
Lipid nanoparticle patent	Lipid composition and particle structure	Usually separate
Formulation patent	Stability, buffer, concentration, or dosage form	Usually separate
Method-of-use patent	Treatment of a defined disease or patient population	Usually separate
Manufacturing patent	Solid-phase synthesis, purification, annealing, or scale-up	Usually separate

A marketed siRNA product can require multiple licenses even if U.S. Patent 9,567,582 is expired or does not cover the product. Sequence, conjugate, formulation, manufacturing, and therapeutic-use patents may create independent barriers.

What is the Orange Book status of U.S. Patent 9,567,582?

The patent is not inherently an Orange Book patent. FDA Orange Book listing is tied to patents submitted by an NDA holder for an approved drug and to the statutory listing categories for drug substance, drug product, or approved method of use.[2]

A platform patent covering generic dsRNA architecture ordinarily does not qualify for listing merely because it could read on an approved siRNA product. It would need to be submitted in connection with a specific NDA and satisfy FDA listing requirements.

The practical implications are:

The patent number should not be treated as an Orange Book-listed patent without an NDA-specific listing.
Absence from the Orange Book does not eliminate ordinary patent infringement risk.
A patent not listed in the Orange Book generally does not create the same statutory Paragraph IV notice and 30-month-stay mechanism associated with a listed patent.
Patent litigation can still proceed under 35 U.S.C. § 271 without Orange Book listing.

When does U.S. Patent 9,567,582 lose exclusivity?

The issue date was February 14, 2017. The enforceable term is not determined by the issue date alone. For a utility patent, the standard term generally runs 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and priority-chain issues.[3]

The claim text supplied does not establish:

the earliest effective nonprovisional filing date;
patent-term adjustment;
any terminal disclaimer;
patent-term extension;
whether the patent is expired, lapsed, or subject to a post-grant proceeding; or
the status of continuation or divisional members.

Accordingly, the patent expiration date must be taken from the USPTO patent record rather than inferred from the 2017 issue date. Patent expiration also must be evaluated separately for continuation patents and related family members.

Are Paragraph IV challenges likely?

A Paragraph IV challenge is relevant only if a generic applicant files an ANDA referencing an approved product and the patent is listed for that product in the Orange Book.

For a broad dsRNA platform patent, the commercial challenge paths are more likely to involve:

A patent-certification strategy for listed product patents.
An inter partes review or post-grant validity challenge.
A declaratory judgment action.
A non-infringement position based on strand length, absence of a 3′ overhang, enzymatic production, or lack of the claimed chemical analogue.
A validity position based on anticipation, obviousness, written description, enablement, or indefiniteness.

The most vulnerable features from an invalidity perspective are broad numerical ranges and functional language covering conventional siRNA architectures. Potential prior-art issues would likely focus on earlier disclosures of 19-23 nucleotide duplexes, 3′ overhangs, chemical synthesis, and target-specific RNAi. The patent's strength would depend on the full prosecution history, priority documents, cited references, claim construction, and any terminal disclaimer.

What patent litigation affects this patent?

The supplied information does not identify litigation, settlements, licenses, or a court ruling specific to U.S. Patent 9,567,582. The patent number alone does not establish whether it has been asserted, challenged, licensed, or included in a settlement.

For freedom-to-operate purposes, litigation should be separated into:

cases naming U.S. 9,567,582 directly;
cases involving continuation or divisional patents in the same family;
cases involving related RNAi platform patents;
product litigation involving approved siRNAs; and
disputes involving sequence, conjugate, lipid nanoparticle, or manufacturing patents.

A settlement involving a related family member does not automatically establish a license or covenant covering this patent.

How strong is the patent estate?

The claim estate is broad in subject matter but likely exposed to substantial validity and claim-construction pressure.

Strengths

Three independent composition claims cover overlapping but distinct structural formats.
The claims reach both unmodified and modified dsRNA.
The 3′-overhang limitation maps onto common siRNA architecture.
Claims cover synthetic chemical production and post-administration processing.
The target categories encompass human, mammalian, plant, viral, tumor-associated, autoimmune, and pathogen-associated RNA.

Limitations

The patent does not claim a specific therapeutic sequence.
It does not claim a specific delivery system.
It does not claim a defined disease treatment regimen.
The 19-52 nucleotide range may encounter broad prior art.
Functional RNAi language may require factual proof of activity.
Product-specific patents can provide independent protection after this platform patent expires.
Claim 20's blunt-end language may create construction issues when read with the overhang requirement.

The patent is most commercially relevant where a product has a conventional siRNA duplex, a 3′ overhang, chemical modifications, and a demonstrated RNAi mechanism. It is less directly relevant to single-stranded RNA medicines, messenger RNA products, antisense oligonucleotides, CRISPR guide RNAs, or delivery systems that do not use the claimed dsRNA structure.

What generic and biosimilar entry risks exist?

Biosimilar law is generally not the principal pathway for chemically synthesized siRNA products. These products are typically regulated as drugs rather than biologics, and an abbreviated pathway may involve an ANDA, a 505(b)(2) application, or another FDA route depending on the reference product and product differences.[4]

Entry risks include:

Risk	Impact
Listed product patent	May trigger Paragraph IV certification and litigation
Platform patent	May create composition infringement exposure
Sequence patent	Can block the intended target sequence
Conjugate patent	May block GalNAc or other ligand attachment
Formulation patent	May block the approved dosage form
Manufacturing patent	May require process redesign or licensing
Method-of-use patent	May limit the proposed indication
Regulatory exclusivity	May delay approval independent of patent term

For an approved siRNA, the largest commercial risk usually comes from the combined patent estate rather than one broad platform patent. A generic manufacturer may design around one claim set while remaining exposed to sequence, conjugate, formulation, or use patents.

What licensing issues are relevant?

The patent claims could have value in:

platform licensing for siRNA developers;
non-exclusive manufacturing licenses;
sequence-specific product licenses;
formulation and delivery collaborations;
university or biotechnology-originated RNAi portfolios;
freedom-to-operate packages for generic or follow-on developers.

A license to a related RNAi patent does not establish coverage of U.S. Patent 9,567,582 unless the agreement defines the licensed patents or patent family broadly enough to include it. Commercial diligence should examine ownership history, assignments, exclusive-license filings, sublicensing rights, field restrictions, geographic scope, and royalty stacking.

Key Takeaways

U.S. Patent 9,567,582 claims broad dsRNA compositions capable of target-specific RNA interference.
The central structural features are 19-52 nucleotide strands or duplex regions and at least one 3′ overhang.
Claims cover conventional 2′-modified, phosphorothioate-containing, chemically synthesized, and terminally modified siRNAs.
The patent reaches therapeutic and diagnostic compositions but does not itself claim a particular drug, delivery vehicle, or disease regimen.
It is not inherently an Orange Book patent. Listing depends on submission in connection with a specific approved NDA.
A Paragraph IV challenge would be relevant only if the patent is listed for an approved product.
Expiration must be determined from the complete USPTO priority and term-adjustment record, not from the 2017 issue date.
Product clearance requires review of sequence, conjugate, formulation, manufacturing, method-of-use, and continuation-family patents.
The estate has broad potential coverage but faces prior-art, enablement, claim-construction, and functional-language risks.

Frequently Asked Questions

Does U.S. Patent 9,567,582 cover siRNA drugs such as Onpattro or Givlaari?

It may be relevant to products using chemically synthesized double-stranded siRNA with the claimed strand lengths, 3′ overhang, chemical modifications, and RNAi activity. Product-specific sequence, conjugate, formulation, and delivery patents must be analyzed separately.

Does a 21-mer siRNA with a two-nucleotide 3′ overhang fall within the claims?

It can. A 21-mer duplex with a two-nucleotide 3′ overhang may satisfy claims 1, 2, 3, 14, and 15 if it also satisfies the isolation, processing, and RNAi-function limitations.

Are 2′-O-methyl and 2′-fluoro modifications covered?

They may fall within the sugar-modified nucleotide analogue language in claims 6-8, 26-28, and 32-34, depending on their location and the construction of the claimed 2′-OH replacement groups.

Does the patent cover siRNA delivery by lipid nanoparticles?

The claims do not expressly require or claim lipid nanoparticles. A lipid nanoparticle may be used with a claimed RNA molecule, but the lipid composition would ordinarily require separate patent analysis.

Can a generic manufacturer avoid the patent by using a blunt-ended duplex?

Potentially, but only if the product avoids all enforceable claims. A blunt-ended design may avoid claims requiring a 3′ overhang, yet claims must be assessed as a complete set and claim 20 may require separate construction.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,567,582.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
35 U.S.C. §§ 154, 156, 271.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application and 505(b)(2) application pathways.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	00126325	Dec 1, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1407044	⤷ Start Trial	132019000000031	Italy	⤷ Start Trial
Austria	373724	⤷ Start Trial
Austria	450621	⤷ Start Trial
Austria	542899	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,567,582

Summary for Patent: 9,567,582